Dr Shu-jun Cheng is the CEO of CHNALT and one of China’s leading toxicologists and key opinion leaders when it comes to alternative, animal-free testing methods. He is a professor at Shanghai Jiao Tong University, one of China’s most prestigious universities and research centers.
“We are very pleased to be able to initiate a formal collaboration with such an active and well-respected champion of animal-free testing in China. Dr. Cheng is a strong voice and has been driving the development of alternative testing methods in China for many years. As SenzaGen’s partner, he can offer expertise and direct contact with industry and gradually establish GARD as the first-choice method for animal-free testing. We see many opportunities arising and this collaboration will ensure we are fully prepared the day the market is ready for our products”, says Anki Malmborg Hager, CEO of SenzaGen.
SenzaGen’s strategy is to establish strong partnerships in markets where animal testing is prohibited or where a ban is expected to be introduced. So far, animal data are mostly compulsory for allergy testing of substances in China, but there are strong forces for introducing alternative methods and in the long term a ban.
“We are looking forward to driving the change within the industry and academia together with SenzaGen. Our ambition is to make alternative methods accepted for chemicals and cosmetics testing in China. We also firmly believe that GARD assays, as next generation genome-based testing methods, will serve as high-performance tools supporting the research and development of safer, allergy-free products”, says Shu-jun Cheng, CEO of CHNALT.
GARD™ is a genome-based test that has higher reliability than other available test methods on the market. The test gives customers important safety information about the risk of chemical substances causing allergies in humans.
For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com | Telephone: +46 768 284822
Tina Dackemark Lawesson, Director Investor Relations & Corporate Communications
Email: tina.lawesson@senzagen.com | Telephone: +46 708 202944
About GARD™
GARD™ is a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. By analyzing hundreds of markers, GARD® generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today’s standard method – tests on mice – which only achieve 70-75 percent precision. SenzaGen’s test can also quantify the allergenic potential of a chemical substance.
About SenzaGen
SenzaGen makes it possible to replace animal experiments with genetic tests in test tubes in order to assess whether the chemicals we come into contact with in our everyday life are allergenic or not. Examples are cosmetics, pharmaceuticals, foods and dyes. The company’s proprietary tests are the most reliable on the market and provide more information than traditional evaluation methods. The tests are sold in-house in Sweden and the US, and through partners in several other countries. Over the next few years, the company will expand geographically, add more distribution partners and launch new, unique tests. SenzaGen has its head office in Lund and subsidiary in the US. For more information, visit http://www.senzagen.com.
SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA).FNCA Sweden AB,+46(0)8-528 00 399 info@fnca.se,is the company’s Certified Adviser. For more information, please visit http://www.senzagen.com.
Attached file
SenzaGen takes a first step into China – cooperates with leading expert
Dr Shu-jun Cheng is the CEO of CHNALT and one of China’s leading toxicologists and key opinion leaders when it comes to alternative, animal-free testing methods. He is a professor at Shanghai Jiao Tong University, one of China’s most prestigious universities and research centers.
“We are very pleased to be able to initiate a formal collaboration with such an active and well-respected champion of animal-free testing in China. Dr. Cheng is a strong voice and has been driving the development of alternative testing methods in China for many years. As SenzaGen’s partner, he can offer expertise and direct contact with industry and gradually establish GARD as the first-choice method for animal-free testing. We see many opportunities arising and this collaboration will ensure we are fully prepared the day the market is ready for our products”, says Anki Malmborg Hager, CEO of SenzaGen.
SenzaGen’s strategy is to establish strong partnerships in markets where animal testing is prohibited or where a ban is expected to be introduced. So far, animal data are mostly compulsory for allergy testing of substances in China, but there are strong forces for introducing alternative methods and in the long term a ban.
“We are looking forward to driving the change within the industry and academia together with SenzaGen. Our ambition is to make alternative methods accepted for chemicals and cosmetics testing in China. We also firmly believe that GARD assays, as next generation genome-based testing methods, will serve as high-performance tools supporting the research and development of safer, allergy-free products”, says Shu-jun Cheng, CEO of CHNALT.
GARD™ is a genome-based test that has higher reliability than other available test methods on the market. The test gives customers important safety information about the risk of chemical substances causing allergies in humans.
For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com | Telephone: +46 768 284822
Tina Dackemark Lawesson, Director Investor Relations & Corporate Communications
Email: tina.lawesson@senzagen.com | Telephone: +46 708 202944
About GARD™
GARD™ is a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. By analyzing hundreds of markers, GARD® generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today’s standard method – tests on mice – which only achieve 70-75 percent precision. SenzaGen’s test can also quantify the allergenic potential of a chemical substance.
About SenzaGen
SenzaGen makes it possible to replace animal experiments with genetic tests in test tubes in order to assess whether the chemicals we come into contact with in our everyday life are allergenic or not. Examples are cosmetics, pharmaceuticals, foods and dyes. The company’s proprietary tests are the most reliable on the market and provide more information than traditional evaluation methods. The tests are sold in-house in Sweden and the US, and through partners in several other countries. Over the next few years, the company will expand geographically, add more distribution partners and launch new, unique tests. SenzaGen has its head office in Lund and subsidiary in the US. For more information, visit http://www.senzagen.com.
SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA).FNCA Sweden AB,+46(0)8-528 00 399 info@fnca.se,is the company’s Certified Adviser. For more information, please visit http://www.senzagen.com.
Attached file
Skin Sensitization Testing—What’s Next?
Int. J. Mol. Sci. 2019, 20(3), 666; https://doi.org/10.3390/ijms20030666
Gunilla Grundström and Carl A.K. Borrebaeck
Abstract
There is an increasing demand for alternative in vitro methods to replace animal testing, and, to succeed, new methods are required to be at least as accurate as existing in vivo tests. However, skin sensitization is a complex process requiring coordinated and tightly regulated interactions between a variety of cells and molecules. Consequently, there is considerable difficulty in reproducing this level of biological complexity in vitro, and as a result the development of non-animal methods has posed a major challenge. However, with the use of a relevant biological system, the high information content of whole genome expression, and comprehensive bioinformatics, assays for most complex biological processes can be achieved. We propose that the Genomic Allergen Rapid Detection (GARD™) assay, developed to create a holistic data-driven in vitro model with high informational content, could be such an example. Based on the genomic expression of a mature human dendritic cell line and state-of-the-art machine learning techniques, GARD™ can today accurately predict skin sensitizers and correctly categorize skin sensitizing potency. Consequently, by utilizing advanced processing tools in combination with high information genomic or proteomic data, we can take the next step toward alternative methods with the same predictive accuracy as today’s in vivo methods—and beyond.
Keywords
genomics; machine learning; skin sensitization; adverse outcome pathways; next generation in vitro tests
Article online
The use of Genomic Allergen Rapid Detection (GARD) assays to predict the respiratory and skin sensitising potential of e-liquids
Regulatory Toxicology and Pharmacology. Volume 103, April 2019, Pages 158-165 https://doi.org/10.1016/j.yrtph.2019.01.001
Matthew Stevenson, Lukasz Czekala, Liam Simms, Nicole Tschierske, Olivia Larne, Tanvir Walele
Abstract
Electronic cigarettes (e-cigarettes) are an increasingly popular alternative to combustible tobacco cigarettes among smokers worldwide. A growing body of research indicates that flavours play a critical role in attracting and retaining smokers into the e-cigarette category, directly contributing to declining smoking rates and tobacco harm reduction. The responsible selection and inclusion levels of flavourings in e-liquids must be guided by toxicological principles. Some flavour ingredients, whether natural extracts or synthetic, are known allergens. In this study, we used the Genomic Allergen Rapid Detection (GARD) testing strategy to predict and compare the respiratory and skin sensitising potential of three experimental and two commercial e-liquids. These novel, myeloid cell-based assays use changes in the transcriptional profiles of genomic biomarkers that are collectively relevant for respiratory and skin sensitisation. Our initial results indicate that the GARD assays were able to differentiate and broadly classify e-liquids based on their sensitisation potential, which are defined mixtures. Further studies need to be conducted to assess whether and how these assays could be used for the screening and toxicological assessment of e-liquids to support product development and commercialisation.
Keywords
Electronic cigarettesSkin sensitisationRespiratory sensitisationIn vitroAlternative methods
Article on line
SenzaGen meddelar att teckningsoptioner har utnyttjats och att tilldelning av aktier skett
Styrelsen för SenzaGen har beslutat att tilldela 40 875 aktier som tecknats i enlighet med villkoren för teckningsoptionerna som emitterades efter beslut av årsstämman den 8 juni 2015. Med anledning av att Bolaget efter teckningsoptionerna emitterats genomfört en aktiesplit (1:5) har innehavare av teckningsoption rätt att teckna fem aktier i Bolaget per teckningsoption till en teckningskurs om 20 kronor per aktie. Varje aktie har därmed tecknats till en kurs om 20 kronor.
Samtliga aktier har tecknats genom kontant betalning och totalt betalas 817 500 kronor för de tecknade aktierna, vilket kommer att öka Bolagets aktiekapital med 2 043,75 kronor, från 778 900 kronor till 780 943,75 kronor. Antalet aktier ökar med 40 875, från 15 578 000 till 15 618 875 och innebär en utspädning om 0,262 procent av antalet aktier och röster i Bolaget. Efter utnyttjande av 8 175 teckningsoptioner kvarstår 17 675 teckningsoptioner av de 49 250 teckningsoptioner som emitterades den 8 juni 2015, vilket innebär att ytterligare högst 88 375 aktier kan komma att tecknas och tilldelas.
För detaljerade villkor avseende teckningsoptionerna hänvisas till Bolagets hemsida, http://www.senzagen.com.
För mer information, kontakta:
Anki Malmborg Hager, VD, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telefon: 0768 284822
Om GARD®
Genom att analysera hundratals markörer genererar GARD® stora mängder data och levererar resultat med över 90 procents precision. Detta kan jämföras med dagens standardmetod – tester på möss – som endast uppnår 70-75 procents precision. SenzaGens test kan dessutom kvantifiera den allergiframkallande potentialen för en kemisk substans.
Om SenzaGen
SenzaGen gör det möjligt att ersätta djurförsök med genetiska tester i provrör för att bedöma om de kemikalier vi kommer i kontakt med i vår vardag är allergiframkallande. Det kan till exempel handla om kosmetika, läkemedel, livsmedel och färgämnen. Bolagets patentskyddade tester är de mest tillförlitliga på marknaden och ger mer information än traditionella utvärderingsmetoder. Testerna säljs i egen regi i Sverige och USA, och genom partners i flera andra länder. De närmaste åren kommer bolaget expandera geografiskt, knyta till sig fler distributionspartners och lansera nya, unika tester. SenzaGen har sitt huvudkontor i Lund och dotterbolag i USA. För mer information, besök http://www.senzagen.com.
Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 28 januari 2019, kl. 08:30.
SenzaGen är listat på Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, är bolagets Certified Adviser. Mer information om SenzaGen finns att tillgå via http://www.senzagen.com.
Bifogat dokument
Merry Christmas and a Happy New Year!
SenzaGens attended BioFIT in Lille, France
On December 4-5, SenzaGen was attending BioFIT in Lille, France. BioFIT is a business development meeting with focus on early stage innovations including pre-clinical stage assets. We met with CROs and life science companies from all over Europe in search of screening tools at pre-clinical stage. Read more about Biofit here: https://www.biofit-event.com
SenzaGen attends Society of Toxicology (STC) of Canada’s 50th Annual Symposium
SenzaGen is attending the Society of Toxicology (STC) of Canada’s 50th Annual Symposium, on December 10-12 in Toronto, Canada. Joshua Schmidt, Business Development Director Americas at SenzaGen, will participate at the symposium and present the poster: GARD – Assessing Skin and Respiratory Sensitizers in vitro using a genomics-based platform.
STC is a non-profit association whose objectives are to promote the acquisition, facilitate the dissemination, and encourage the utilization of knowledge in the science of toxicology. They support continuing education and excellence in research through its Annual Symposium, which provides a venue for members and international experts to present the latest advances in experimental and regulatory toxicology.
To book a meeting, please email Joshua Schmidt at:
joshua.schmidt (a) senzagen.com
Hope to see you there!
For more information about the symposium, please visit:
https://www.fourwav.es/view/803/info/
SenzaGen förstärker med IR-och kommunikationsansvarig
“SenzaGen befinner sig i en mycket spännande fas och vi behöver förstärka vår organisation inom såväl IR som strategisk kommunikation. Tina Dackemark Lawesson kommer som kommunikationsansvarig att ha uppdraget att driva kommunikationen gentemot våra prioriterade målgrupper och kommer därmed att ha en nyckelposition på SenzaGen”, säger Anki Malmborg Hager, VD på SenzaGen.
Tina Dackemark Lawesson kommer närmast från en roll som Director Investor Relations & Corporate Communications på kommunikationsutrustningsbolaget Invisio i Köpenhamn, dessförinnan har hon haft liknande befattningar på Cellavision, Enzymatica och Precise Biometrics.
”SenzaGen är ett mycket spännande bolag som med sin teknologi har möjlighet att lämna ett bestående avtryck. Det känns därför extra roligt och utmanande att få vara med och utveckla bolagets kommunikation framöver”, säger Tina Dackemark Lawesson, ny IR- och kommunikationsansvarig på SenzaGen.
För mer information, kontakta:
Anki Malmborg Hager, VD, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telefon: 0768 284822
Tina Dackemark Lawesson, SenzaGen AB
Email: tina.lawesson@senzagen.com
Telefon: 0708 202944
Om GARD®
GARD® är en grupp med tester för analys av kemikaliers förmåga att starta en allergisk reaktion hos människa. Genom att analysera hundratals markörer genererar GARD™ stora mängder data och levererar resultat med över 90 procents precision. Detta kan jämföras med dagens standardmetod – tester på möss – som endast uppnår 70-75 procents precision. SenzaGens test kan dessutom kvantifiera den allergiframkallande potentialen för en kemisk substans.
Om SenzaGen
SenzaGen gör det möjligt att ersätta djurförsök med genetiska tester i provrör för att bedöma om de kemikalier vi kommer i kontakt med i vår vardag är allergiframkallande. Det kan till exempel handla om kosmetika, läkemedel, livsmedel och färgämnen. Bolagets patentskyddade tester är de mest tillförlitliga på marknaden och ger mer information än traditionella utvärderingsmetoder. Testerna säljs i egen regi i Sverige och USA, och genom partners i flera andra länder. De närmaste åren kommer bolaget expandera geografiskt, knyta till sig fler distributionspartners och lansera nya, unika tester. SenzaGen har sitt huvudkontor i Lund och dotterbolag i USA. För mer information, besök http://www.senzagen.com.
Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 5 december 2018 kl. 08.30.
SenzaGen är listat på Nasdaq Stockholm First North (ticker: SENZA). FNCA är bolagets Certified Adviser. Mer information om SenzaGen finns att tillgå via http://www.senzagen.com.
Bifogat dokument
SenzaGen strengthens its organization with IR and communications director
“SenzaGen is in a very exciting development phase and we need to strengthen our organization within both IR and strategic communication. In her role as communications director, Tina will be tasked with increasing communication towards our prioritized target groups and will thus have a key position in SenzaGen,” says Anki Malmborg Hager, CEO of SenzaGen.
Dackemark Lawesson joins SenzaGen from Invisio, a Danish communication equipment company based in Copenhagen, where she was Director of Investor Relations & Corporate Communications. She previously held similar positions at Cellavision, Enzymatica and Precise Biometrics.
“SenzaGen is a very exciting company which, thanks to its technology, has the opportunity to make a real impact in the pharmaceutical and cosmetics industries. I am therefore delighted to have the opportunity of meeting the challenge of taking the company’s communications forward,” says Dackemark Lawesson.
For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822
Tina Dackemark Lawesson, SenzaGen AB
Email: tina.lawesson@senzagen.com
Telephone: +46 708 202944
About GARD®
GARD® is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90 percent reliability.
This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75 percent. SenzaGen’s tests are also capable of measuring the potency of a substance’s allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.
About SenzaGen
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in Delaware USA. For more information visit http://www.senzagen.com
The information was submitted for publication, through the contact person set out above on December 5, 2018, at 08.30.
SenzaGen AB is listed on Nasdaq First North in Stockholm and FNCA is the company’s Certified Adviser. For more information, please visit http://www.senzagen.com
Attached file
SenzaGen speaks at Eurofins Human Safety Seminar, November 29
Dr Andy Forreryd, scientist at SenzaGen, is one of three speakers at the Human Safety Seminar organised by Eurofins BioPharma Product Testing Munich where he will be presenting the GARD® platform for skin and respiratory sensitization. The seminar will be hosted on November 29 at the new laboratory and office building of Eurofins Munich, Robert-Koch-Straße 3a in Planegg near Munich, Germany.
The topics for the seminar are:
For more information and registration:
https://www.eurofins.com/human-safety-seminar